ARLINGTON, Va., May 5 /PRNewswire/ -- BioInformatics, LLC announces the release of its newest report, Capitalizing on New Opportunities for Stem Cell Products. Despite a sluggish economy and cuts being made to laboratory budgets, the market for stem cell research products is expected to increase substantially over the next several years to $688.9 M in 2009 and just under one billion at the end of 2011. Suppliers of stem cell related products are in need of a fast, accurate assessment of new opportunities in the stem cell research products market. In this report, BioInformatics, LLC (http://www.gene2drug.com), the premier research and advisory firm serving the life science market, fielded a detailed 60-question survey to scientists worldwide about their current--and planned--areas of stem cell research, usage of stem cell products and preferred suppliers.

The report will be available at pre-release pricing until May 17, 2009. This special pricing is at a significant reduction off the regular pricing which will take effect on Monday, May 18, 2009.

Life science suppliers can use this study to determine areas poised for growth (i.e., the market for stem cell culture media, sera, supplements and cell lines) in the stem cell research market, identify potential key competitors (including percentage of products purchased from each major supplier), and plan a long-term strategy to secure a leading position in this expanding market. The report includes detailed market share estimates across major stem cell product categories by market segment, geographic region and top suppliers.

In this report, scientists specify percentage of stem cell culture products purchased from each of the following suppliers:

    ATCC
    BD Biosciences (a part of Becton, Dickinson and Co., NYSE:   BDX)
    CellGenix
    Life Technologies (Nasdaq:   LIFE)
    Lonza (SWX: LONN)
    Millipore (NYSE:    MIL)
    Miltenyi Biotec
    R&D Systems (division of TECHNE Corp., Nasdaq:   TECH)
    Sigma-Aldrich (divisions: SAFC Biosciences, Nasdaq:   SIAL)
    Stem Cell Sciences (AIM: STEM)
    Stemcell Technologies
    Thermo Fisher Scientific (Hyclone, NYSE:    TMO)
    Zen Bio

As with any valuable research tool, it is important to obtain a better understanding of how stem cells are used in the lab and in particular, what differentiated cell types are of major interest. Although it may not come as a surprise to suppliers that the majority of respondents differentiate their stem cells into hematopoeitic and epithelial cells, other cell types are expected to be of increasing interest over the next couple of years. By 2011, osteogenic cells in particular, but also endothelial, cardiomyocytes, chondrocytes, and dendritic cells are projected to be differentiated states as common as hematopoeitic and epithelial cells. These findings have implications for product development as the cell types of interest will dictate the kinds of products that researchers will need to conduct their research and study various diseases.

"There is tremendous excitement, especially in the academic community, over the recent Executive Order signed by President Barack Obama rescinding the restriction on federal funding of human embryonic stem cell research," notes Tamara Zemlo, Ph.D., MPH, Vice President of Advisory Services. "However, the exploration of induced pluripotent stem cells and the pursuit of cell-based therapies and drug discovery and development research using adult human stem cells continues to provide great promise." Zemlo has been the senior analyst on over 80 syndicated market research reports, and consulted with multiple stem cell product vendors to optimize the relevance of this study with regards to the current stem cell research market.

To learn more about this report, a complimentary Executive Summary is available at http://www.gene2drug.com/reports/201/.

ABOUT BIOINFORMATICS, LLC

BioInformatics, LLC is the premier research and advisory firm serving the life science industry. By leveraging our professional social network of more than 43,000 biomedical researchers, we have supported more than 300 companies and provided insights that lead to better business decisions. Our assignments include assessing the size and attractiveness of markets, optimizing product configurations and pricing, validating corporate acquisitions, measuring customer loyalty, and evaluating brand strength and positioning.

    For more information contact:

    Mary Follin
    Manager, Marketing/Sales
    BioInformatics, LLC
    2111 Wilson Blvd., Suite 250
    Arlington, VA  22201
    703.778.3080 x13 (phone)
    m.follin@gene2drug.com
    http://www.gene2drug.com/

SOURCE BioInformatics, LLC

Back to top

RELATED LINKS
http://www.gene2drug.com